Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | TDP2 | O95551 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878200 | 1.00 | MALT1 (0.56) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL878201 | 1.00 | MALT1 (0.56) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL18771056 | 0.90 | MALT1 (0.48) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL18774056 | 0.85 | MALT1 (0.65) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL12473069 | 0.85 | MALT1 (0.65) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL12473212 | 0.85 | MALT1 (0.68) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL12473163 | 0.83 | MALT1 (0.62) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL18774057 | 0.81 | MALT1 (0.60) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL12473165 | 0.81 | MALT1 (0.61) | MALT1IDO1ALDH1A1KDM4EMEN1 | |
| SCHEMBL12473035 | 0.81 | MALT1 (0.61) | MALT1IDO1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9631041-B2 | PH-sensitive compositions for delivery of beta lapachone and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-25 | — | — | US | disclosed |
| US-9631041-B2 | PH-sensitive compositions for delivery of beta lapachone and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-25 | — | — | US | disclosed |
| US-9469878-B2 | Methods of treating cancer comprising targeting NQO1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469878-B2 | Methods of treating cancer comprising targeting NQO1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-10-18 | — | — | US | disclosed |
| US-20130253046-A1 | METHODS OF TREATING CANCER COMPRISING TARGETING NQO1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253046-A1 | METHODS OF TREATING CANCER COMPRISING TARGETING NQO1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012039855-A1 | PH-SENSITIVE COMPOSITIONS FOR DELIVERY OF BETA LAPACHONE AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040492-A1 | METHODS OF TREATING CANCER COMPRISING TARGETING NQO1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012039855-A1 | PH-SENSITIVE COMPOSITIONS FOR DELIVERY OF BETA LAPACHONE AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040513-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF BETA LAPACHONE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253046-A1 | METHODS OF TREATING CANCER COMPRISING TARGETING NQO1 | NQO1, KEAP1, GSTK1 | MALT1 3920/4885IDO1 2064/4885ALDH1A1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.